{"groups":[{"description":"Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses.\n\nBevacizumab: Given IV\n\nCarboplatin: Given IV\n\nComputed Tomography: Correlative studies\n\nPaclitaxel: Given IV","id":"FG000","title":"Arm I (Adjuvant Chemotherapy Suboptimally Debulked)"},{"description":"Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses. Patients undergo interval cytoreductive surgery between courses 3 and 4.\n\nBevacizumab: Given IV\n\nCarboplatin: Given IV\n\nComputed Tomography: Correlative studies\n\nPaclitaxel: Given IV\n\nTherapeutic Conventional Surgery: Undergo surgery","id":"FG001","title":"Arm II (Neoadjuvant Chemotherapy)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"346"},{"groupId":"FG001","numSubjects":"346"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"346"},{"groupId":"FG001","numSubjects":"346"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"112 additional women, whose treatment was not randomized, enrolled onto this study in order to evaluate whether findings from perfusion imaging are prognostic. This report focuses on the randomized treatment component of this study.","recruitmentDetails":"Newly diagnosed women with high-risk early stage or advanced stage epithelial ovarian cancer enrolled from September 27, 2010 to February 8, 2012.These women were randomly assigned to receive either carboplatin (AUC 6) combined with either paclitaxel 175 mg/m2 q 21 days or paclitaxel 80mg/m2 on days 1, 8 and 15. Bevacizumab was optional."}